Pyrotinib
- Generic Name
- Pyrotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT03923179
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03910712
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03843749
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 59
- Registration Number
- NCT03772353
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756064
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 355
- Registration Number
- NCT03588091
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Huai'an First People's Hospital, Huaian, Jiangsu, China
🇨🇳The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Conditions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 14
- Registration Number
- NCT03412383
- Locations
- 🇨🇳
Fei Ma, Beijing, Beijing, China
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 279
- Registration Number
- NCT02973737
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT02834936
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳HR-BLTN-II-NSCLC Investigational Site, Zhengzhou, China
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Tongji University
- Target Recruit Count
- 40
- Registration Number
- NCT02535507
- Locations
- 🇨🇳
Department of Oncology, Shanghai pulmonary hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.